PhoreMost
Cambridge, GB · 12 known investors
PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
Investors · 12
Amadeus Capital PartnersLondon · $50K – $12.7M
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Cambridge Angels groupCambridge · $195K – $1.9M
University of Cambridge EnterpriseCambridge
Amadeus Capital SAreported · 2 sourcesGeneva
O2h VenturesreportedCambridge
Parkwalk AdvisorsreportedLondon
Also in the syndicate · 5
BGFleadMorningside VenturesTrend Investment GroupXtalPi IncXtalPi Inc.
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BSep 2024 · 4 sources
BGF (lead), Parkwalk Advisors (lead), Astellas Venture Management, Morningside Ventures, o2h ventures, Trend Investment Group, XtalPi Inc, XtalPi Inc.
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does PhoreMost do?
- PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
- Who are PhoreMost's investors?
- PhoreMost's investors include Amadeus Capital Partners, Astellas Venture Management LLC, Cambridge Angels group, University of Cambridge Enterprise, Amadeus Capital SA, O2h Ventures, Parkwalk Advisors.
- Where is PhoreMost headquartered?
- PhoreMost is headquartered in Cambridge, GB.